NO-GO: UNVEILING THE POWER OF C-08 FOR THE TREATMENT OF OVER ACTIVE BLADDER

Project description

Clinical validation of natural product for the treatment of overactive bladder symptoms

Overactive bladder (OAB) syndrome, with urinary symptoms of urgency and nocturia, affects 500 million people worldwide, with prevalence increase with age (>30 % over 75 years old). Icelandic SagaNatura has developed NO-GO, a natural product from the leaves of Angelica archangelica for improving OAB symptoms as a non-prescription urinary product. Its efficiency and safety were recently clinically validated in a small-scale clinical trial on 66 patients with OAB. The current EU-funded NO-GO phase2 project aims to fine-tune the formulation, increase the production capacity and extend the clinical validation. The objective is to prepare the product for expansion in Europe and North American markets.

Fields of science

• natural sciences › biological sciences › ecology › ecosystems

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

SAGANATURA EHF

Net EU contribution

€ 1 562 729,00

Address

Sudurhellu 8
221 Hafnarfjordur
Iceland

Region

Ísland › Ísland › Höfuðborgarsvæði

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 669 741,00